Final answer:
NMDA receptor antagonists are currently in development for negative symptoms of schizophrenia. Hence the correct answer is option A
Step-by-step explanation:
Drugs acting in this mechanism that are currently in development for negative symptoms of schizophrenia are a) NMDA receptor antagonists. These drugs work by blocking the NMDA receptors, which are involved in regulating dopamine neurotransmission. By blocking these receptors, NMDA receptor antagonists can help reduce the overactivity of dopamine neurotransmission associated with negative symptoms of schizophrenia.